LUCD · Lucid Diagnostics Inc.

Lucid Diagnostics reported first quarter 2026 financial results, highlighting revenue growth to $1.3 million from $0.8 million in the same period last year, driven by processing 3,177 EsoGuard tests. Operating expenses remained relatively flat at $13.4 million, while GAAP net loss improved to $13.9 million from $26.9 million, partly due to lower other expenses. Non-GAAP adjusted loss narrowed to $10.5 million from $11.2 million. The company strengthened its balance sheet with a $17 million public offering, ending the quarter with $27.9 million in cash (proforma $45 million), extending its runway into 2027. Management emphasized confidence in securing Medicare coverage as a key catalyst, while continuing to build commercial momentum through health system and payor engagement. The company also highlighted a strong presence at Digestive Disease Week and a forthcoming clinical practice guideline update recommending EsoGuard and EsoCheck.